Literature DB >> 22346496

Passive protection of diabetic rats with antisera specific for the polysaccharide portion of the lipopolysaccharide isolated from Pseudomonas pseudomallei.

L E Bryan1, S Wong, D E Woods, D A Dance, W Chaowagul.   

Abstract

Polyclonal and monoclonal antisera raised to tetanus toxoid-conjugated polysaccharide of lipopolysaccharide (lps) and purified lps of Pseudomonas pseudomallei that reacted with a collection of 41 strains of this bacterium from 23 patients are described. The common antigen recognized by these sera was within the polysaccharide component of the lps of the cells. The sera were specific for P pseudomallei in that none of 37 strains of other bacteria, including 20 Gram-negative and three Gram-positive species, were recognized, although cross-reaction occurred using the anticonjugate serum with some strains of Pseudomonas cepacia serotype A, a closely related bacterium. Passive protection studies using a diabetic rat model of P pseudomallei infection showed that partially purified rabbit polyclonal and mouse monoclonal antisera were protective when the median lethal dose was raised by four to five orders of magnitude. The wide distribution of the polysaccharide antigen among isolates of P pseudomallei used in this study and the protective role of antibody to the conjugated polysaccharide antigen suggest potential as a vaccine.

Entities:  

Keywords:  Lipopolysaccharide; Melioidosis; Pseudomonas pseudomallei; Vaccine

Year:  1994        PMID: 22346496      PMCID: PMC3250846          DOI: 10.1155/1994/856850

Source DB:  PubMed          Journal:  Can J Infect Dis        ISSN: 1180-2332


  20 in total

1.  Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.

Authors:  S J Cryz; J C Sadoff; E Fürer; R Germanier
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

2.  Pseudomonas aeruginosa immunotype 5 polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; E Furer; J C Sadoff; R Germanier
Journal:  Infect Immun       Date:  1986-04       Impact factor: 3.441

3.  Production of hemolysin and other extracellular enzymes by clinical isolates of Pseudomonas pseudomallei.

Authors:  L R Ashdown; J M Koehler
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

4.  Serum resistance associated with virulence in Yersinia enterocolitica.

Authors:  C H Pai; L DeStephano
Journal:  Infect Immun       Date:  1982-02       Impact factor: 3.441

5.  Homogeneity of lipopolysaccharide antigens in Pseudomonas pseudomallei.

Authors:  T L Pitt; H Aucken; D A Dance
Journal:  J Infect       Date:  1992-09       Impact factor: 6.072

6.  Prevalence of antibodies to Pseudomonas pseudomallei exotoxin and whole cell antigens in military personnel in Sabah and Sarawak, Malaysia.

Authors:  N Embi; A Suhaimi; R Mohamed; G Ismail
Journal:  Microbiol Immunol       Date:  1992       Impact factor: 1.955

7.  Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis.

Authors:  G Gladman; P J Connor; R F Williams; T J David
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

8.  Antigenic relationships among penicillin-binding proteins 1 from members of the families Pasteurellaceae and Enterobacteriaceae.

Authors:  A B Schryvers; S S Wong; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1986-10       Impact factor: 5.191

9.  The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment.

Authors:  D A Dance; V Wuthiekanun; W Chaowagul; N J White
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  25 in total

1.  Isolation of polymyxin B-susceptible mutants of Burkholderia pseudomallei and molecular characterization of genetic loci involved in polymyxin B resistance.

Authors:  M N Burtnick; D E Woods
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Humoral and cell-mediated adaptive immune responses are required for protection against Burkholderia pseudomallei challenge and bacterial clearance postinfection.

Authors:  Gareth D Healey; Stephen J Elvin; Margaret Morton; E Diane Williamson
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Fate of a Burkholderia pseudomallei lipopolysaccharide mutant in the mouse macrophage cell line RAW 264.7: possible role for the O-antigenic polysaccharide moiety of lipopolysaccharide in internalization and intracellular survival.

Authors:  S Arjcharoen; C Wikraiphat; M Pudla; K Limposuwan; D E Woods; S Sirisinha; P Utaisincharoen
Journal:  Infect Immun       Date:  2007-06-18       Impact factor: 3.441

4.  Burkholderia pseudomallei capsular polysaccharide conjugates provide protection against acute melioidosis.

Authors:  Andrew E Scott; Mary N Burtnick; Margaret G M Stokes; Adam O Whelan; E Diane Williamson; Timothy P Atkins; Joann L Prior; Paul J Brett
Journal:  Infect Immun       Date:  2014-05-27       Impact factor: 3.441

5.  Revised structures for the predominant O-polysaccharides expressed by Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Christian Heiss; Mary N Burtnick; Rosemary A Roberts; Ian Black; Parastoo Azadi; Paul J Brett
Journal:  Carbohydr Res       Date:  2013-08-24       Impact factor: 2.104

Review 6.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition.

Authors:  Shauna L Reckseidler-Zenteno; Rebekah DeVinney; Donald E Woods
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

8.  Molecular and physical characterization of Burkholderia mallei O antigens.

Authors:  Mary N Burtnick; Paul J Brett; Donald E Woods
Journal:  J Bacteriol       Date:  2002-02       Impact factor: 3.490

9.  Contribution of murine IgG Fc regions to antibody binding to the capsule of Burkholderia pseudomallei.

Authors:  Michael J Dillon; Rachael A Loban; Dana E Reed; Peter Thorkildson; Kathryn J Pflughoeft; Sujata G Pandit; Paul J Brett; Mary N Burtnick; David P AuCoin
Journal:  Virulence       Date:  2016-04-20       Impact factor: 5.882

10.  Monoclonal antibodies passively protect BALB/c mice against Burkholderia mallei aerosol challenge.

Authors:  Sylvia R Treviño; Amy R Permenter; Marilyn J England; Narayanan Parthasarathy; Paul H Gibbs; David M Waag; Tran C Chanh
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.